Dany Gholam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dany Gholam has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Ahmad Al-Jijakli
Institut Gustave-Roussy
1 shared publicationJean-Henri Bourhis
Institut Gustave-Roussy
1 shared publicationJean-Marie Vantelon
Institut Gustave-Roussy
1 shared publication
Latest Publications
- 30 July 2003
- Published by Springer Nature in Annals of Hematology
- Vol. 82 (12) , 766-768
A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody
Multicentric Castleman's disease (MCD) is a rare systemic lymphoproliferative disorder with too few patient series reported in the literature to have a clear idea about the etiology, outcome and the best treatment available. Systemic reactive amyloidosis is a very rare complication of MCD and its presence worsens the prognosis. We report a case of a 28-year-old patient with plasma-cell type, human immunodeficiency virus (HIV)-negative and human herpesvirus-8 (HHV-8)-negative MCD who responded to treatment with chemotherapy and the anti-CD20 monoclonal antibody, rituximab. Anti-CD20 therapy could be an interesting adjunctive treatment in MCD.
- 30 July 2003
- Published by Springer Nature in Annals of Hematology
- Vol. 82 (12) , 766-768
A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody
Multicentric Castleman's disease (MCD) is a rare systemic lymphoproliferative disorder with too few patient series reported in the literature to have a clear idea about the etiology, outcome and the best treatment available. Systemic reactive amyloidosis is a very rare complication of MCD and its presence worsens the prognosis. We report a case of a 28-year-old patient with plasma-cell type, human immunodeficiency virus (HIV)-negative and human herpesvirus-8 (HHV-8)-negative MCD who responded to treatment with chemotherapy and the anti-CD20 monoclonal antibody, rituximab. Anti-CD20 therapy could be an interesting adjunctive treatment in MCD.